Explore more topics
SEC reporting owner

Novartis Bioventures Ltd SEC insider disclosures

Explore Novartis Bioventures Ltd's reporting-owner identity, issuer relationships, purchases, sales and SEC filing receipts.

As of 2026-10-13T06:40:31.983Z

Reporting owner CIK
0001297709
Issuers
14
Coverage
verified
Jump to a section

What is a Form 4?

Animation: what a Form 4 is, shown with one real example. Sonic Automotive (SAH) reporting owner Paul P. Rusnak bought 13,701 shares at $59.78 on Wednesday, October 7, 2026, transaction code P, an open-market purchase (S is a sale and A is an award from the company). A timeline marks the SEC's two-business-day filing deadline, which ends Friday, October 9. The SEC accepted the Form 4 at 4:33:21 PM ET on October 9, and NexusTrade treats it as public one minute later, at 4:34:21 PM ET. A lamp for NexusTrade's InsiderTrades indicator stays off from the trade date until that moment, then counts one purchase worth 13,701 × $59.78 = $819,045.78.
In this example the shares were bought on Oct 7, 2026, and NexusTrade's InsiderTrades indicator can count the purchase starting at 4:34:21 PM ET on Oct 9, one minute after the SEC accepted the Form 4.

A Form 4 is the SEC filing a company insider, such as an officer, director or 10% owner, uses to report a trade in the company's stock, generally within two business days. The animation follows one real filing as an example: Paul P. Rusnak's purchase of Sonic Automotive (SAH) shares on October 7, 2026.

The same reading applies to every row on this page. The trade date is when the shares changed hands. The available date is when NexusTrade treats the filing as public, and a NexusTrade InsiderTrades indicator counts a purchase (code P) or sale (code S) only from that moment. Code A awards are not counted as purchases.

Issuer relationships

A reporting-owner CIK identifies the filer across issuer relationships and name aliases. A filer may be an individual or an organization; the filing role is the relevant evidence.

Show the table · 14 rows, 5 columns

Scroll sideways to compare all columns. Select a heading to sort.

Marina Biotech, Inc.0000737207MRNANoNo
Celladon Corp0001305253CLDNNoNo
Akebia Therapeutics, Inc.0001517022AKBANoNo
Tokai Pharmaceuticals Inc0001404281TKAINoNo
PROTEOSTASIS THERAPEUTICS, INC.0001445283PTINoNo
Aeglea BioTherapeutics, Inc.0001636282AGLENoNo
Ra Pharmaceuticals, Inc.0001481512RARXNoNo
Aerpio Pharmaceuticals, Inc.0001422142ARPONoNo
Altimmune, Inc.0001326190ALTNoNo
AILERON THERAPEUTICS INC0001420565ALRNNoNo
BICYCLE THERAPEUTICS plc0001761612BCYCNoNo
Galera Therapeutics, Inc.0001563577GRTXNoNo
Forma Therapeutics Holdings, Inc.,0001538927FMTXNoNo
Akouos, Inc.0001722271AKUSNoNo
Marina Biotech, Inc. ↗Celladon Corp ↗Akebia Therapeutics, Inc. ↗Tokai Pharmaceuticals Inc ↗PROTEOSTASIS THERAPEUTICS, INC. ↗Aeglea BioTherapeutics, Inc. ↗Ra Pharmaceuticals, Inc. ↗Aerpio Pharmaceuticals, Inc. ↗Altimmune, Inc. ↗AILERON THERAPEUTICS INC ↗BICYCLE THERAPEUTICS plc ↗Galera Therapeutics, Inc. ↗Forma Therapeutics Holdings, Inc., ↗Akouos, Inc. ↗

Recent SEC transactions

Code P identifies a purchase, S a sale and A an award. Awards and open-market purchases describe different events. Use the public availability date when deciding when a researcher could have known about the transaction.

Show the table · 0 rows, 6 columns

Scroll sideways to compare all columns. Select a heading to sort.

No records are available for this view.

Up to 50 transactions from the recent two-year owner window.

Source evidence and strategy eligibility

The transactions below come from filings; a historical tracker separately simulates following eligible events. Joint filers can report the same transaction, and an owner can have filings at multiple companies. Public availability, amendment lineage and verified coverage determine which events a historical tracker may use.

The current directory marks this owner's filing coverage verified.